Overview We are a clinical-stage biopharmaceutical company developing our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancers. Our conditionally active biologics (CAB or CABs) capitalize on our proprietary discoveries with respect to tumor biology, enabling us to target known and widely validated tumor antigens that have previously been difficult or impossible to target. Our novel CAB therapeutic candidates exploit characteristic pH d...
Q2 FY2026 — expected 2026-09-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001193125-26-134499 | EDGAR | 102K words |
| 2025-03-28 | 2024-12-31 | 0000950170-25-046217 | EDGAR | — |
| 2024-03-26 | 2023-12-31 | 0000950170-24-036548 | EDGAR | — |
| 2023-03-23 | 2022-12-31 | 0000950170-23-009551 | EDGAR | — |
| 2022-02-28 | 2021-12-31 | 0000950170-22-002303 | EDGAR | — |
| 2021-03-24 | 2020-12-31 | 0001193125-21-092812 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001193125-25-280435 | EDGAR | 61K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-105220 | EDGAR | — |
| 2025-05-06 | 2025-03-31 | 0000950170-25-064594 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123506 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0000950170-24-094164 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0000950170-24-059757 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0000950170-23-060389 | EDGAR | — |
| 2023-08-01 | 2023-06-30 | 0000950170-23-036554 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021358 | EDGAR | — |
| 2022-11-04 | 2022-09-30 | 0000950170-22-022036 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0000950170-22-016149 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0000950170-22-007871 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-07-16 | 0001193125-26-306117 | EDGAR | — |
| 2026-04-02 | 0001193125-26-140053 | EDGAR | 1K words |
| 2026-03-31 | 0001193125-26-134501 | EDGAR | — |
| 2026-03-23 | 0001193125-26-119698 | EDGAR | — |
| 2026-03-02 | 0001539497-26-000812 | EDGAR | — |
| 2026-02-09 | 0001193125-26-041852 | EDGAR | — |
| 2026-02-06 | 0001193125-26-041367 | EDGAR | — |
| 2026-01-30 | 0001193125-26-031942 | EDGAR | — |
| 2026-01-12 | 0001193125-26-010458 | EDGAR | — |
| 2025-12-31 | 0001193125-25-337646 | EDGAR | — |
101 total filings indexed. 73 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001826892 |
| Ticker | BCAB |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.bioatla.com |
| Listed | 2020-12-16 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/BCAB (~200 tokens, structured JSON with cryptographic provenance)